Renaissance Technologies (RenTech)'s TRDA Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 202,084 shares of Entrada Therapeutics, Inc. (TRDA) worth $2.55 M, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in TRDA, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 214,800 shares. Largest reduction occurred in Q4 2025, reducing 341,665 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Entrada Therapeutics (TRDA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Entrada Therapeutics (TRDA) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -50,551 | Reduce 20.01% | 202,084 | $12.62 |
| Q4 2025 | -341,665 | Reduce 57.49% | 252,635 | $10.28 |
| Q3 2025 | +214,800 | Add 56.60% | 594,300 | $5.80 |
| Q2 2025 | +51,015 | Add 15.53% | 379,500 | $6.72 |
| Q1 2025 | +162,285 | Add 97.64% | 328,485 | $9.04 |
| Q4 2024 | +72,400 | Add 77.19% | 166,200 | $17.29 |
| Q3 2024 | +49,200 | Add 110.31% | 93,800 | $15.98 |
| Q2 2024 | +44,600 | New Buy | 44,600 | $14.25 |
| Q2 2022 | -11,800 | Sold Out | 0 | $0.00 |
| Q1 2022 | -1,773 | Reduce 13.06% | 11,800 | $9.41 |
| Q4 2021 | +13,573 | New Buy | 13,573 | $17.09 |
Renaissance Technologies (RenTech)'s Entrada Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Entrada Therapeutics, Inc. (TRDA) in Q4 2021, acquiring 13,573 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Entrada Therapeutics, Inc. (TRDA) for 11 quarters since Q4 2021.
Renaissance Technologies (RenTech)'s largest addition to Entrada Therapeutics, Inc. (TRDA) was in Q3 2025, adding 594,300 shares worth $3.45 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 202,084 shares of Entrada Therapeutics, Inc. (TRDA), valued at approximately $2.55 M.
As of the Q1 2026 filing, Entrada Therapeutics, Inc. (TRDA) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Entrada Therapeutics, Inc. (TRDA) was 594,300 shares, as reported at the end of Q3 2025.